Quince Therapeutics Reveals First Patient Dosed In Phase 3 Clinical Trial Of EryDex For Treatment Of Ataxia-Telangiectasia; This Pivotal Phase 3 Study Will Be Conducted Under A Special Protocol Assessment Agreement With The U.S. FDA
Portfolio Pulse from Benzinga Newsdesk
Quince Therapeutics has dosed the first patient in its Phase 3 clinical trial of EryDex for the treatment of Ataxia-Telangiectasia. This pivotal study is being conducted under a Special Protocol Assessment agreement with the U.S. FDA.
June 25, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quince Therapeutics has initiated its Phase 3 clinical trial for EryDex, targeting Ataxia-Telangiectasia, under a Special Protocol Assessment with the FDA. This milestone could significantly impact the company's stock price.
The initiation of a Phase 3 clinical trial under a Special Protocol Assessment with the FDA is a significant milestone. It indicates regulatory alignment and potential for successful trial outcomes, which could positively impact QNCX's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100